BCS Core

BCS核心

• 批准号: 10289606
• 负责人: Julie Lynn Boerner
• 金额: $ 12.56万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10289606
• 关键词: African American; Ancillary Study; Biological; Biological Assay; Biological Specimen database; Cancer Patient; Charge; Clinical; Collection; Communities; Comprehensive Cancer Center; Confidentiality of Patient Information; Core Facility; Data; Development; Diagnosis; Disease; Doctor of Philosophy; Ensure; Ethnic Origin; Freezing; Future; Genomics; Goals; Guidelines; Histologic; Human; Institutes; Institutional Review Boards; Malignant Neoplasms; Malignant neoplasm of lung; Microscopic; Minority; Molecular; Nature; Outcome; Pathologic; Pathologist; Pathology; Patient Care; Patients; Process; Prognosis; Prognostic Marker; Program Research Project Grants; Protocols documentation; Quality Control; Race; Research; Research Personnel; Research Project Grants; Research Support; Resource Development; Resource Sharing; Sampling; Sampling Studies; Science; Services; Specimen; Stains; System; Technology; Testing; Therapeutic Intervention; Time; Tissue Microarray; Tissue Sample; Tissue Stains; Tissues; Translational Research; Update; Xenograft procedure; accurate diagnosis; base; biobank; cancer biomarkers; cancer health disparity; cancer risk; cancer therapy; design; health disparity; human tissue; improved; innovation; metropolitan; molecular array; neoplasm resource; new therapeutic target; novel; patient population; programs; therapeutic biomarker; therapeutic development

Project Summary The Biospecimen Core directed by the Director of the Biobanking and Correlative Sciences (BCS) Core at Karmanos Cancer Institute, Dr. Julie Boerner, PhD and co-directed by Dr. Fulvio Lonardo, expert lung cancer pathologist will provide the highest quality biological specimens to support the research of investigators for this P20 application. This Core facility is charged with collecting, banking, and transferring fresh and frozen human tissue samples for investigative purposes. As part of this process, the Biospecimen Core will provide correlative clinical information for biospecimens while maintaining strict patient confidentiality, using the well-established Honest Broker system, and ensuring that requesting investigators have proper protocol review and IRB approval. This specific collection of biospecimens is focused on overcoming the lack of biospecimens from minority patients that plagues race/ethnicity-related researcher questions. The goal of this P20 SPORE Core is to ensure that high-quality biospecimens, collected while ensuring compliance with federal and institutional guidelines, are delivered in a timely manner to P20 SPORE investigators and to provide pathologic and molecular analytic expertise to support the innovative and translational cancer health disparities research projects in this application. The specific aims of Biospecimen Core are the following: Specific Aim 1: To collect, process and bank cancer tissue and associated biological samples with ongoing quality control to ensure timely distribution of appropriately diagnosed, high-quality samples to investigators and collaborators on all P20 SPORE projects for molecular and genomic analysis, for culture and for xenograft assays, and for ancestry informative markers to further define patient race; Specific Aim 2: Perform high quality immunohistochemical staining and provide pathological interpretation of stained tissue sections to investigators and collaborators on all P20 SPORE projects; Specific Aim 3: Generate tissue microarrays using samples from African American cancer patients for use in future projects and made available to the broader research community to support expanded efforts in the reduction of cancer health disparities; Specific Aim 4: To maintain and update a central Detroit P20 SPORE database of biospecimens from cancer patients collected at KCI that is annotated with demographic, clinical, and pathologic data, and provide access to data and specimens; and Specific Aim 5: To actively participate in the design of pathology/ancillary studies of P20 SPORE projects, the Developmental Research Program projects, and projects for consideration for a full P50 SPORE application, including providing input on suitability for samples for studies proposed, histologic characterization, immunohistochemical analyses, and microscopic scoring, and construction of study specific tissue microarrays. Together, these aims will allow the Biospecimen Core to have a significant clinical impact in this P20 application, as it has a large collection of valuable and appropriate specimens that are immediately available to the research projects.

项目摘要 生物样本核心由生物库和相关科学（BCS）核心主任指导， Karmanos癌症研究所，Julie Boerner博士，博士，由肺癌专家Fulvio Lonardo博士共同指导 病理学家将提供最高质量的生物标本，以支持研究人员的研究， P20应用程序。这个核心设施负责收集、储存和转移新鲜和冷冻的人类 用于调查的组织样本作为这一过程的一部分，生物样本核心将提供相关的 生物标本的临床信息，同时严格维护患者机密性，使用完善的 诚实经纪人制度，并确保提出请求的研究者有适当的方案审查和IRB批准。 这一特定的生物标本收集的重点是克服缺乏生物标本的少数民族 困扰种族/民族相关研究人员问题的患者。此P20 SPORE核心的目标是确保 在确保符合联邦和机构指导方针的同时收集的高质量生物标本， 及时交付给P20 SPORE研究人员，并提供病理和分子分析 专业知识，以支持创新和转化癌症健康差异研究项目，在这方面 应用程序.生物标本核心的具体目标如下：具体目标1：收集、处理和 储存癌组织和相关生物样本，并进行持续的质量控制，以确保及时分发 为所有P20 SPORE项目的研究者和合作者提供适当诊断的高质量样本 用于分子和基因组分析、用于培养和用于异种移植测定以及用于祖先信息标记 进一步确定患者种族;具体目标2：进行高质量免疫组织化学染色， 向研究者和合作者提供所有P20 SPORE的染色组织切片的病理学解释 具体目标3：使用来自非裔美国人癌症患者的样本生成组织微阵列， 在未来的项目中使用，并提供给更广泛的研究界，以支持在 减少癌症健康差异;具体目标4：维护和更新底特律市中心的P20 SPORE 来自在KCI收集的癌症患者的生物样本的数据库，其用人口统计学，临床， 具体目标5：积极参与 P20 SPORE项目的病理学/辅助研究设计，发展研究计划 项目，以及考虑全面P50 SPORE应用的项目，包括提供有关适用性的意见 对于拟定研究的样本，组织学表征、免疫组织化学分析和显微镜检查 评分和构建研究特异性组织微阵列。总之，这些目标将使生物标本 核心在此P20应用中具有显著的临床影响，因为它收集了大量有价值的 研究项目可以立即获得适当的标本。